PXPulse Podcast
19th September 2024
This podcast episode, AVAC (AIDS Vaccine Advocacy Coalition)  takes a deep dive into the twice-yearly injectable LEN for PrEP to share the science, what made PURPOSE 1 a success, and what’s next to ensure effective and equitable delivery of this groundbreaking prevention product.

This episode features perspective from Principal Investigator, Dr. Flavia Kiweewa of Makerere University – Johns Hopkins University (MU-JHU), Chilufya Kasanda Hampongo of Zambia’s Treatment Advocacy and Literacy Campaign (TALC), and AVAC’s Executive Director, Mitchell Warren.

#LEN  #PrEP results

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Press Release | Foster City, Calif. – June 20, 2024- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.